Pharming (PHAR) Net Income towards Common Stockholders (2020 - 2026)
Pharming (PHAR) posted Net Income towards Common Stockholders of -$5.2 million for Q1 2026, down 98358590.57% on a QoQ basis from $5.3 in Q4 2025, and up 64.58% year-over-year from -$3.2 million in Q1 2025.
Pharming (PHAR) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Pharming's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$5.2 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 64.58% year-over-year to -$5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$15.2 million (up 62.12% YoY) and the FY2025 annual result came in at $2.9 million, up 124.08% from the prior year.
- Net Income towards Common Stockholders was -$5.2 million for Q1 2026 at Pharming, down from $5.3 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $28.3 million in Q4 2022 and bottomed at -$14.7 million in Q1 2025.
- A 5-year average of -$1.2 million and a median of -$1.1 in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders plunged 1051230869.23% — and 2025, when it surged 781.82%.
- Pharming's Net Income towards Common Stockholders stood at $28.3 million in 2022, then sank by 100.0% to -$7.4 in 2023, then slumped by 160013413.51% to -$11.8 million in 2024, then surged by 100.0% to $5.3 in 2025, then plunged by 98358590.57% to -$5.2 million in 2026.
- Business Quant data shows PHAR's Net Income towards Common Stockholders at -$5.2 million in Q1 2026, $5.3 in Q4 2025, and $7.5 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Pharming | 8.69 Bn | 8.64 Bn | 65.80 Mn | -5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.21 Mn |
| Dec 31, 2025 | 5.30 |
| Sep 30, 2025 | 7.50 |
| Jun 30, 2025 | -10.03 Mn |
| Mar 31, 2025 | -14.72 Mn |
| Dec 31, 2024 | -11.84 Mn |
| Sep 30, 2024 | -1.10 |
| Jun 30, 2024 | -13.67 Mn |
| Mar 31, 2024 | -12.45 Mn |
| Dec 31, 2023 | -7.40 |
| Sep 30, 2023 | 3.46 Mn |
| Jun 30, 2023 | 1.30 |
| Mar 31, 2023 | -12.21 Mn |
| Dec 31, 2022 | 28.30 Mn |
| Sep 30, 2022 | 9.10 Mn |
| Jun 30, 2022 | 15.70 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |
| Jun 30, 2021 | 12.22 Mn |